Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia".

Perrotti D, Agarwal A, Lucas CM, Narla G, Neviani P, Odero MD, Ruvolo PP, Verrills NM.

Sci Transl Med. 2019 Jul 17;11(501). pii: eaau0416. doi: 10.1126/scitranslmed.aau0416.

PMID:
31316003
2.

Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance.

Staudt D, Murray HC, McLachlan T, Alvaro F, Enjeti AK, Verrills NM, Dun MD.

Int J Mol Sci. 2018 Oct 16;19(10). pii: E3198. doi: 10.3390/ijms19103198. Review.

3.

Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.

Degryse S, de Bock CE, Demeyer S, Govaerts I, Bornschein S, Verbeke D, Jacobs K, Binos S, Skerrett-Byrne DA, Murray HC, Verrills NM, Van Vlierberghe P, Cools J, Dun MD.

Leukemia. 2018 Dec;32(12):2731. doi: 10.1038/s41375-018-0241-7.

PMID:
30232463
4.

Cell-Free DNA Blood Collection Tubes Are Appropriate for Clinical Proteomics: A Demonstration in Colorectal Cancer.

Almazi JG, Pockney P, Gedye C, Smith ND, Hondermarck H, Verrills NM, Dun MD.

Proteomics Clin Appl. 2018 May;12(3):e1700121. doi: 10.1002/prca.201700121. Epub 2018 Mar 30.

5.

Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.

Degryse S, de Bock CE, Demeyer S, Govaerts I, Bornschein S, Verbeke D, Jacobs K, Binos S, Skerrett-Byrne DA, Murray HC, Verrills NM, Van Vlierberghe P, Cools J, Dun MD.

Leukemia. 2018 Mar;32(3):788-800. doi: 10.1038/leu.2017.276. Epub 2017 Aug 30. Erratum in: Leukemia. 2018 Dec;32(12):2731.

6.

Functional importance of PP2A regulatory subunit loss in breast cancer.

Watt LF, Panicker N, Mannan A, Copeland B, Kahl RGS, Dun MD, Young B, Roselli S, Verrills NM.

Breast Cancer Res Treat. 2017 Nov;166(1):117-131. doi: 10.1007/s10549-017-4403-5. Epub 2017 Jul 25.

PMID:
28744751
7.

Targeting PP2A and proteasome activity ameliorates features of allergic airway disease in mice.

Nair PM, Starkey MR, Haw TJ, Liu G, Horvat JC, Morris JC, Verrills NM, Clark AR, Ammit AJ, Hansbro PM.

Allergy. 2017 Dec;72(12):1891-1903. doi: 10.1111/all.13212. Epub 2017 Jun 21.

PMID:
28543283
8.

Harnessing the power of proteomics for identification of oncogenic, druggable signalling pathways in cancer.

Murray HC, Dun MD, Verrills NM.

Expert Opin Drug Discov. 2017 May;12(5):431-447. doi: 10.1080/17460441.2017.1304377. Epub 2017 Mar 17. Review.

PMID:
28286965
9.

Peripheral Lipopolysaccharide Challenge Induces Long-Term Changes in Tyrosine Hydroxylase Regulation in the Adrenal Medulla.

Ong LK, Page S, Briggs GD, Guan L, Dun MD, Verrills NM, Dunkley PR, Dickson PW.

J Cell Biochem. 2017 Aug;118(8):2096-2107. doi: 10.1002/jcb.25839. Epub 2017 Apr 18.

PMID:
27958651
10.

Expression of renin-angiotensin system (RAS) components in endometrial cancer.

Delforce SJ, Lumbers ER, Corbisier de Meaultsart C, Wang Y, Proietto A, Otton G, Scurry J, Verrills NM, Scott RJ, Pringle KG.

Endocr Connect. 2017 Jan;6(1):9-19. doi: 10.1530/EC-16-0082. Epub 2016 Dec 12.

11.

The phosphorylated form of FTY720 activates PP2A, represses inflammation and is devoid of S1P agonism in A549 lung epithelial cells.

Rahman MM, Prünte L, Lebender LF, Patel BS, Gelissen I, Hansbro PM, Morris JC, Clark AR, Verrills NM, Ammit AJ.

Sci Rep. 2016 Nov 16;6:37297. doi: 10.1038/srep37297.

12.

Treatment of inflammatory arthritis via targeting of tristetraprolin, a master regulator of pro-inflammatory gene expression.

Ross EA, Naylor AJ, O'Neil JD, Crowley T, Ridley ML, Crowe J, Smallie T, Tang TJ, Turner JD, Norling LV, Dominguez S, Perlman H, Verrills NM, Kollias G, Vitek MP, Filer A, Buckley CD, Dean JL, Clark AR.

Ann Rheum Dis. 2017 Mar;76(3):612-619. doi: 10.1136/annrheumdis-2016-209424. Epub 2016 Sep 5.

13.

TLR2 ligation induces corticosteroid insensitivity in A549 lung epithelial cells: Anti-inflammatory impact of PP2A activators.

Rahman MM, Prabhala P, Rumzhum NN, Patel BS, Wickop T, Hansbro PM, Verrills NM, Ammit AJ.

Int J Biochem Cell Biol. 2016 Sep;78:279-287. doi: 10.1016/j.biocel.2016.07.030. Epub 2016 Jul 28.

PMID:
27477309
14.

Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors.

Smith AM, Dun MD, Lee EM, Harrison C, Kahl R, Flanagan H, Panicker N, Mashkani B, Don AS, Morris J, Toop H, Lock RB, Powell JA, Thomas D, Guthridge MA, Moore A, Ashman LK, Skelding KA, Enjeti A, Verrills NM.

Oncotarget. 2016 Jul 26;7(30):47465-47478. doi: 10.18632/oncotarget.10167.

15.

Development of novel PP2A activators for use in the treatment of acute myeloid leukaemia.

Toop HD, Dun MD, Ross BK, Flanagan HM, Verrills NM, Morris JC.

Org Biomol Chem. 2016 May 18;14(20):4605-16. doi: 10.1039/c6ob00556j.

PMID:
27102578
16.

A systematic evaluation of the safety and toxicity of fingolimod for its potential use in the treatment of acute myeloid leukaemia.

Enjeti AK, D'Crus A, Melville K, Verrills NM, Rowlings P.

Anticancer Drugs. 2016 Jul;27(6):560-8. doi: 10.1097/CAD.0000000000000358.

17.

Activating protein phosphatase 2A (PP2A) enhances tristetraprolin (TTP) anti-inflammatory function in A549 lung epithelial cells.

Rahman MM, Rumzhum NN, Hansbro PM, Morris JC, Clark AR, Verrills NM, Ammit AJ.

Cell Signal. 2016 Apr;28(4):325-34. doi: 10.1016/j.cellsig.2016.01.009. Epub 2016 Jan 26.

PMID:
26820662
18.

Theophylline Represses IL-8 Secretion from Airway Smooth Muscle Cells Independently of Phosphodiesterase Inhibition. Novel Role as a Protein Phosphatase 2A Activator.

Patel BS, Rahman MM, Rumzhum NN, Oliver BG, Verrills NM, Ammit AJ.

Am J Respir Cell Mol Biol. 2016 Jun;54(6):792-801. doi: 10.1165/rcmb.2015-0308OC.

PMID:
26574643
19.

Basal protein phosphatase 2A activity restrains cytokine expression: role for MAPKs and tristetraprolin.

Rahman MM, Rumzhum NN, Morris JC, Clark AR, Verrills NM, Ammit AJ.

Sci Rep. 2015 May 18;5:10063. doi: 10.1038/srep10063.

20.

PR55α-containing protein phosphatase 2A complexes promote cancer cell migration and invasion through regulation of AP-1 transcriptional activity.

Gilan O, Diesch J, Amalia M, Jastrzebski K, Chueh AC, Verrills NM, Pearson RB, Mariadason JM, Tulchinsky E, Hannan RD, Dhillon AS.

Oncogene. 2015 Mar 5;34(10):1340. doi: 10.1038/onc.2014.460. No abstract available.

PMID:
25740609
21.

Involvement of vacuolar H(+)-ATPase in killing of human melanoma cells by the sphingosine kinase analogue FTY720.

Tay KH, Liu X, Chi M, Jin L, Jiang CC, Guo ST, Verrills NM, Tseng HY, Zhang XD.

Pigment Cell Melanoma Res. 2015 Mar;28(2):171-83. doi: 10.1111/pcmr.12326. Epub 2014 Nov 13.

PMID:
25358761
22.

Activity-associated miRNA are packaged in Map1b-enriched exosomes released from depolarized neurons.

Goldie BJ, Dun MD, Lin M, Smith ND, Verrills NM, Dayas CV, Cairns MJ.

Nucleic Acids Res. 2014 Aug;42(14):9195-208. doi: 10.1093/nar/gku594. Epub 2014 Jul 22.

23.

PR55α-containing protein phosphatase 2A complexes promote cancer cell migration and invasion through regulation of AP-1 transcriptional activity.

Gilan O, Diesch J, Amalia M, Jastrzebski K, Chueh AC, Verrills NM, Pearson RB, Mariadason JM, Tulchinsky E, Hannan RD, Dhillon AS.

Oncogene. 2015 Mar 5;34(10):1333-9. doi: 10.1038/onc.2014.26. Epub 2014 Mar 17. Erratum in: Oncogene. 2015 Mar 5;34(10):1340.

PMID:
24632621
24.

Dephosphorylation of CaMKII at T253 controls the metaphase-anaphase transition.

Hoffman A, Carpenter H, Kahl R, Watt LF, Dickson PW, Rostas JA, Verrills NM, Skelding KA.

Cell Signal. 2014 Apr;26(4):748-56. doi: 10.1016/j.cellsig.2013.12.015. Epub 2014 Jan 7.

PMID:
24407174
25.

Suppression of PP2A is critical for protection of melanoma cells upon endoplasmic reticulum stress.

Tay KH, Jin L, Tseng HY, Jiang CC, Ye Y, Thorne RF, Liu T, Guo ST, Verrills NM, Hersey P, Zhang XD.

Cell Death Dis. 2012 Jun 28;3:e337. doi: 10.1038/cddis.2012.79.

26.

PP2A phosphatase suppresses function of the mesenchymal invasion regulator NEDD9.

Bradbury P, Mahmassani M, Zhong J, Turner K, Paul A, Verrills NM, O'Neill GM.

Biochim Biophys Acta. 2012 Feb;1823(2):290-7. doi: 10.1016/j.bbamcr.2011.10.011. Epub 2011 Oct 28.

27.

Identification of novel diagnostic biomarkers for asthma and chronic obstructive pulmonary disease.

Verrills NM, Irwin JA, He XY, Wood LG, Powell H, Simpson JL, McDonald VM, Sim A, Gibson PG.

Am J Respir Crit Care Med. 2011 Jun 15;183(12):1633-43. doi: 10.1164/rccm.201010-1623OC. Epub 2011 Mar 18.

PMID:
21471098
28.

Essential role of protein phosphatase 2A in metaphase II arrest and activation of mouse eggs shown by okadaic acid, dominant negative protein phosphatase 2A, and FTY720.

Chang HY, Jennings PC, Stewart J, Verrills NM, Jones KT.

J Biol Chem. 2011 Apr 22;286(16):14705-12. doi: 10.1074/jbc.M110.193227. Epub 2011 Mar 7.

29.

Controlling the cell cycle: the role of calcium/calmodulin-stimulated protein kinases I and II.

Skelding KA, Rostas JA, Verrills NM.

Cell Cycle. 2011 Feb 15;10(4):631-9. Epub 2011 Feb 15. Review.

PMID:
21301225
30.

Protein phosphatase 2A carboxymethylation and regulatory B subunits differentially regulate mast cell degranulation.

Kranias G, Watt LF, Carpenter H, Holst J, Ludowyke R, Strack S, Sim AT, Verrills NM.

Cell Signal. 2010 Dec;22(12):1882-90. doi: 10.1016/j.cellsig.2010.07.017. Epub 2010 Aug 2.

PMID:
20688157
31.

Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers.

Roberts KG, Smith AM, McDougall F, Carpenter H, Horan M, Neviani P, Powell JA, Thomas D, Guthridge MA, Perrotti D, Sim AT, Ashman LK, Verrills NM.

Cancer Res. 2010 Jul 1;70(13):5438-47. doi: 10.1158/0008-5472.CAN-09-2544. Epub 2010 Jun 15.

32.

Regulation of CaMKII by phospho-Thr253 or phospho-Thr286 sensitive targeting alters cellular function.

Skelding KA, Suzuki T, Gordon S, Xue J, Verrills NM, Dickson PW, Rostas JA.

Cell Signal. 2010 May;22(5):759-69. doi: 10.1016/j.cellsig.2009.12.011. Epub 2010 Jan 11.

PMID:
20060891
33.

A role for altered microtubule polymer levels in vincristine resistance of childhood acute lymphoblastic leukemia xenografts.

Ong V, Liem NL, Schmid MA, Verrills NM, Papa RA, Marshall GM, Mackenzie KL, Kavallaris M, Lock RB.

J Pharmacol Exp Ther. 2008 Feb;324(2):434-42. Epub 2007 Nov 6.

PMID:
17986648
34.

FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.

Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, Druker BJ, Cortes J, Marcucci G, Chen CS, Verrills NM, Roy DC, Caligiuri MA, Bloomfield CD, Byrd JC, Perrotti D.

J Clin Invest. 2007 Sep;117(9):2408-21.

35.

Clinical proteomics: present and future prospects.

Verrills NM.

Clin Biochem Rev. 2006 May;27(2):99-116.

36.

Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia.

Verrills NM, Po'uha ST, Liu ML, Liaw TY, Larsen MR, Ivery MT, Marshall GM, Gunning PW, Kavallaris M.

J Natl Cancer Inst. 2006 Oct 4;98(19):1363-74.

PMID:
17018783
37.

Mast cell function: regulation of degranulation by serine/threonine phosphatases.

Sim AT, Ludowyke RI, Verrills NM.

Pharmacol Ther. 2006 Nov;112(2):425-39. Epub 2006 Jun 21. Review.

PMID:
16790278
38.

Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia--an in vivo study.

Verrills NM, Liem NL, Liaw TY, Hood BD, Lock RB, Kavallaris M.

Proteomics. 2006 Mar;6(5):1681-94.

PMID:
16456880
39.

Improving the targeting of tubulin-binding agents: lessons from drug resistance studies.

Verrills NM, Kavallaris M.

Curr Pharm Des. 2005;11(13):1719-33. Review.

PMID:
15892670
40.

Tissue-specific tropomyosin isoform composition.

Schevzov G, Vrhovski B, Bryce NS, Elmir S, Qiu MR, O'neill GM, Yang N, Verrills NM, Kavallaris M, Gunning PW.

J Histochem Cytochem. 2005 May;53(5):557-70.

PMID:
15872049
41.

Neuronal-associated microtubule proteins class III beta-tubulin and MAP2c in neuroblastoma: role in resistance to microtubule-targeted drugs.

Don S, Verrills NM, Liaw TY, Liu ML, Norris MD, Haber M, Kavallaris M.

Mol Cancer Ther. 2004 Sep;3(9):1137-46.

42.

A fluorescent natural product for ultra sensitive detection of proteins in one-dimensional and two-dimensional gel electrophoresis.

Mackintosh JA, Choi HY, Bae SH, Veal DA, Bell PJ, Ferrari BC, Van Dyk DD, Verrills NM, Paik YK, Karuso P.

Proteomics. 2003 Dec;3(12):2273-88.

PMID:
14673778
43.

Proteome analysis of vinca alkaloid response and resistance in acute lymphoblastic leukemia reveals novel cytoskeletal alterations.

Verrills NM, Walsh BJ, Cobon GS, Hains PG, Kavallaris M.

J Biol Chem. 2003 Nov 14;278(46):45082-93. Epub 2003 Aug 29.

44.

Microtubule alterations and mutations induced by desoxyepothilone B: implications for drug-target interactions.

Verrills NM, Flemming CL, Liu M, Ivery MT, Cobon GS, Norris MD, Haber M, Kavallaris M.

Chem Biol. 2003 Jul;10(7):597-607.

PMID:
12890533
45.

Drug resistance mechanisms in cancer cells: a proteomics perspective.

Verrills NM, Kavallaris M.

Curr Opin Mol Ther. 2003 Jun;5(3):258-65. Review.

PMID:
12870435
46.

Anticancer therapy with novel tubulin-interacting drugs.

Kavallaris M, Verrills NM, Hill BT.

Drug Resist Updat. 2001 Dec;4(6):392-401. Review.

PMID:
12030786
47.
48.

Subproteomics based upon protein cellular location and relative solubilities in conjunction with composite two-dimensional electrophoresis gels.

Cordwell SJ, Nouwens AS, Verrills NM, Basseal DJ, Walsh BJ.

Electrophoresis. 2000 Apr;21(6):1094-103. Review.

PMID:
10786883
49.

The microbial proteome database--an automated laboratory catalogue for monitoring protein expression in bacteria.

Cordwell SJ, Nouwens AS, Verrills NM, McPherson JC, Hains PG, Van Dyk DD, Walsh BJ.

Electrophoresis. 1999 Dec;20(18):3580-8.

PMID:
10612284

Supplemental Content

Loading ...
Support Center